Latest Clinical Trials News

Page 2 of 140
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
Anteris Technologies reported a wider third-quarter loss as spending accelerated on its PARADIGM heart-valve trial and manufacturing expansion. The company ended September with US$236.3 million in cash, but also retained unresolved weaknesses in financial reporting controls.
Ada Torres
Ada Torres
11 Nov 2026
EBR Systems delivered higher reimbursement, manufacturing and revenue milestones in the third quarter, but a sharp September slowdown and a formal going-concern warning have shifted attention to execution and funding. The company says it holds US$93.2 million in cash, cash equivalents and marketable securities, while US$41.8 million of debt falls due within 12 months.
Victor Sage
Victor Sage
10 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Pathkey.AI has presented Chipforge as a functioning end-to-end AI platform for chip design, backed by independent testing, benchmark comparisons and a first proof-of-value contract. The harder test now is converting that engineering progress into recurring revenue before its A$5.8 million cash balance becomes a constraint.
Sophie Babbage
Sophie Babbage
5 Nov 2026
Neurizon says it has removed its remaining Obsidian convertible notes while targeting $6.3 million in new equity ahead of the pivotal NUZ-001 ALS readout. The funding plan reduces immediate conversion uncertainty, but the proposed Share Purchase Plan and possible future facility drawdown leave execution questions open.
Ada Torres
Ada Torres
5 Nov 2026
Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
Victor Sage
5 Nov 2026

Browse the archive

Full archive